BRAF V600E

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm19
BRAF V600E	Vemurafenib	Predictive	B	Does Not Support Sensitivity Response	4	accepted	EID1405 In this Phase II pilot study (NCT00405587) of BRAF V600 inhibitor vemurafenib in 21 metastatic colorectal cancer (CRC) patients with BRAF V600E, one patient had a durable 21 week partial response, and… (full text at CIViC) PMID 26460303 · Kopetz et al., 2015 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	—	submitted	EID3742 In a clinical study of 122 cancer patients, including 37 previously treated colorectal cancer patients harboring BRAF V600 (V600E=32; V600 unknown=5) mutations, stable disease and progressive disease … (full text at CIViC) PMID 26287849 · Hyman et al., 2015 · Open in CIViC

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Malignant Colorectal Neoplasm19

BRAF V600E

Vemurafenib

Predictive

Does Not Support Sensitivity Response

accepted

EID1405

In this Phase II pilot study (NCT00405587) of BRAF V600 inhibitor vemurafenib in 21 metastatic colorectal cancer (CRC) patients with BRAF V600E, one patient had a durable 21 week partial response, and… (full text at CIViC)

PMID 26460303 · Kopetz et al., 2015 · Open in CIViC

civic

BRAF V600E

Vemurafenib

Predictive

Supports Sensitivity Response

—

submitted

EID3742

In a clinical study of 122 cancer patients, including 37 previously treated colorectal cancer patients harboring BRAF V600 (V600E=32; V600 unknown=5) mutations, stable disease and progressive disease … (full text at CIViC)

PMID 26287849 · Hyman et al., 2015 · Open in CIViC

Malignant Neoplasm6
BRAF V600E	(oncogenic)	Oncogenic	D	Supports Oncogenicity	2	submitted	EID13055 In this study, myc-tagged BRAF V600E (reported as V599E) transiently expressed in COS cells exhibited approximately 478-fold greater basal kinase activity than wild-type BRAF, constitutively activated… (full text at CIViC) PMID 15035987 · Wan et al., 2004 · Open in CIViC	civic
BRAF V600E	Cetuximab	Predictive	D	Does Not Support Sensitivity Response	3	submitted	EID12445 Several BRAF mutant cell lines were analyzed in response to treatment with increasing concentrations of cetuximab (0-300nM). Impact on signalling was measured: ERK signalling by western blot and RAS-G… (full text at CIViC) PMID 28783719 · Yao et al., 2017 · Open in CIViC	civic
BRAF V600E	Cobimetinib	Predictive	D	Supports Sensitivity Response	3	accepted	EID1141 Preclinical study analyzing the differential response to MEK inhibitors in KRAS and BRAF mutant cancer cell lines and mouse xenografts. Inhibition of active, phosphorylated MEK by GDC-0973 (cobimetini… (full text at CIViC) PMID 23934108 · Hatzivassiliou et al., 2013 · Open in CIViC	civic
BRAF V600E	Dabrafenib + TrametinibCombination	Predictive	B	Supports Sensitivity Response	3	accepted	EID11672 This NCI-MATCH trial was conducted in 35 patients of which 29 were included in the primary efficacy analysis with tumors with BRAF V600E mutations, and treated with a combination of dabrafenib and tra… (full text at CIViC) PMID 32758030 · Salama et al., 2020 · Open in CIViC	civic
BRAF V600E OR NRAS Mutation OR HRAS Mutation OR KRAS Mutation OR NF1 Inactivating Mutation	Selumetinib	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID11696 In this Phase II study, 20 patients harboring activating RAS gene mutations (KRAS = 8, NRAS = 3. HRAS = 1), BRAF V600E mutations, and NF1 inactivating mutations (n=7) were treated with Selumetinib. No… (full text at CIViC) PMID 35363510 · Eckstein et al., 2022 · Open in CIViC	civic
BRAF V600E OR NRAS Mutation OR HRAS Mutation OR KRAS Mutation OR NF1 Mutation	Selumetinib	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID11681 In this phase II study of the arm E of the NCI-COG pediatric MATCH trial, 20 patients (median age: 14) were treated with Selumetinib. High-grade glioma (n=7) and rhabdomyosarcoma (n=7) were the most c… (full text at CIViC) PMID 35363510 · Eckstein et al., 2022 · Open in CIViC	civic

Malignant Neoplasm6

BRAF V600E

(oncogenic)

Oncogenic

Supports Oncogenicity

submitted

EID13055

In this study, myc-tagged BRAF V600E (reported as V599E) transiently expressed in COS cells exhibited approximately 478-fold greater basal kinase activity than wild-type BRAF, constitutively activated… (full text at CIViC)

PMID 15035987 · Wan et al., 2004 · Open in CIViC

civic

BRAF V600E

Cetuximab

Predictive

Does Not Support Sensitivity Response

submitted

EID12445

Several BRAF mutant cell lines were analyzed in response to treatment with increasing concentrations of cetuximab (0-300nM). Impact on signalling was measured: ERK signalling by western blot and RAS-G… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

civic

BRAF V600E

Cobimetinib

Predictive

Supports Sensitivity Response

accepted

EID1141

Preclinical study analyzing the differential response to MEK inhibitors in KRAS and BRAF mutant cancer cell lines and mouse xenografts. Inhibition of active, phosphorylated MEK by GDC-0973 (cobimetini… (full text at CIViC)

PMID 23934108 · Hatzivassiliou et al., 2013 · Open in CIViC

civic

BRAF V600E

Dabrafenib + TrametinibCombination

Predictive

Supports Sensitivity Response

accepted

EID11672

This NCI-MATCH trial was conducted in 35 patients of which 29 were included in the primary efficacy analysis with tumors with BRAF V600E mutations, and treated with a combination of dabrafenib and tra… (full text at CIViC)

PMID 32758030 · Salama et al., 2020 · Open in CIViC

civic

BRAF V600E OR NRAS Mutation OR HRAS Mutation OR KRAS Mutation OR NF1 Inactivating Mutation

Selumetinib

Predictive

Does Not Support Sensitivity Response

accepted

EID11696

In this Phase II study, 20 patients harboring activating RAS gene mutations (KRAS = 8, NRAS = 3. HRAS = 1), BRAF V600E mutations, and NF1 inactivating mutations (n=7) were treated with Selumetinib. No… (full text at CIViC)

PMID 35363510 · Eckstein et al., 2022 · Open in CIViC

civic

BRAF V600E OR NRAS Mutation OR HRAS Mutation OR KRAS Mutation OR NF1 Mutation

Selumetinib

Predictive

Does Not Support Sensitivity Response

accepted

EID11681

In this phase II study of the arm E of the NCI-COG pediatric MATCH trial, 20 patients (median age: 14) were treated with Selumetinib. High-grade glioma (n=7) and rhabdomyosarcoma (n=7) were the most c… (full text at CIViC)

PMID 35363510 · Eckstein et al., 2022 · Open in CIViC

civic

Malignant Ovarian Neoplasm2
BRAF V600E	Dabrafenib + TrametinibCombination	Predictive	B	Supports Sensitivity Response	3	submitted	EID7454 In NCI-MATCH trial, patients with advanced solid tumors, lymphoma or multiple myeloma harboring BRAF V600E mutation were treated with dabrafenib and trametinib. Patients with melanoma, thyroid carcino… (full text at CIViC) Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	B	Supports Sensitivity Response	3	accepted	EID5959 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among 4 pati… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic

Malignant Ovarian Neoplasm2

BRAF V600E

Dabrafenib + TrametinibCombination

Predictive

Supports Sensitivity Response

submitted

EID7454

In NCI-MATCH trial, patients with advanced solid tumors, lymphoma or multiple myeloma harboring BRAF V600E mutation were treated with dabrafenib and trametinib. Patients with melanoma, thyroid carcino… (full text at CIViC)

Open in CIViC

civic

BRAF V600E

Vemurafenib

Predictive

Supports Sensitivity Response

accepted

EID5959

The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among 4 pati… (full text at CIViC)

PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC

civic

Malignant Pancreatic Neoplasm1
BRAF V600E AND ERBB2 Amplification AND SMAD4 LOSS AND TP53 V218E	Bevacizumab + Lapatinib + Trametinib + TrastuzumabCombination	Predictive	C	Supports Sensitivity Response	3	submitted	EID11712 In this clinical trial, 18 patients with pancreatic cancer were recruited. In this case, the patient (74 y/F) with pancreatic cancer harboring, BRAF V600E, SMAD4 Loss, ERBB2 amplification, and, TP53 V… (full text at CIViC) PMID 36670111 · Shaya et al., 2023 · Open in CIViC	civic

Malignant Pancreatic Neoplasm1

BRAF V600E AND ERBB2 Amplification AND SMAD4 LOSS AND TP53 V218E

Bevacizumab + Lapatinib + Trametinib + TrastuzumabCombination

Predictive

Supports Sensitivity Response

submitted

EID11712

In this clinical trial, 18 patients with pancreatic cancer were recruited. In this case, the patient (74 y/F) with pancreatic cancer harboring, BRAF V600E, SMAD4 Loss, ERBB2 amplification, and, TP53 V… (full text at CIViC)

PMID 36670111 · Shaya et al., 2023 · Open in CIViC

civic

Malignant Peripheral Nerve Sheath Tumor1
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	—	submitted	EID3788 In a malignant peripheral nerve sheath tumor patient harboring a BRAF V600E mutation, response to vemurafenib monotherapy was reported. Upon identification of the BRAF V600E mutation, the patient was … (full text at CIViC) PMID 24335681 · Kaplan, 2013 · Open in CIViC	civic

Malignant Peripheral Nerve Sheath Tumor1

BRAF V600E

Vemurafenib

Predictive

Supports Sensitivity Response

—

submitted

EID3788

In a malignant peripheral nerve sheath tumor patient harboring a BRAF V600E mutation, response to vemurafenib monotherapy was reported. Upon identification of the BRAF V600E mutation, the patient was … (full text at CIViC)

PMID 24335681 · Kaplan, 2013 · Open in CIViC

civic

Malignant Thyroid Gland Neoplasm11
BRAF V600E	(diagnostic)	Diagnostic	B	Supports Positive	3	accepted	EID79 BRAF V600E is shown to be associated with the tall-cell variant of papillary thyroid cancer. PMID 21594703 · Howell et al., 2011 · Open in CIViC	civic
BRAF V600E	MEK Inhibitor CI-1040	Predictive	B	Supports Sensitivity Response	—	rejected	EID2138 In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5% vs.… (full text at CIViC) PMID 21882184 · Kim et al., 2012 · Open in CIViC	civic
BRAF V600E	MEK Inhibitor CI-1040	Predictive	D	Supports Sensitivity Response	—	submitted	EID2136 Thyroid cancer cell lines with BRAF V600E mutations were more sensitive to the MAPK inhibitor CI-1040 than those with wildtype BRAF (IC50: 0.031-1.251 uM vs. 44.376-278.286 uM). In a mouse xenograft m… (full text at CIViC) PMID 17911174 · Liu et al., 2007 · Open in CIViC	civic
BRAF V600E	PLX4720 + PonatinibCombination	Predictive	D	Supports Sensitivity Response	4	submitted	EID8033 Ghosh et al. provide compelling evidence that thyroid cancers with a BRAFV600E mutation are sensitive to combined PLX4720 and Ponatinib treatment. They predicted a synergistic effect using HTS of acti… (full text at CIViC) PMID 31937621 · Ghosh et al., 2020 · Open in CIViC	civic
BRAF V600E	PLX4720 + PonatinibCombination	Predictive	D	Supports Sensitivity Response	3	submitted	EID8040 Both in vitro and in vivo models in Kebebew et al. provide evidence that a combinatorial treatment of PLX4720 (a BRAF inhibitor) and ponatinib (a multi targeting tyrosine kinase inhibitor) shows poten… (full text at CIViC) PMID 31937621 · Ghosh et al., 2020 · Open in CIViC	civic
BRAF V600E	RDEA 119	Predictive	B	Supports Sensitivity Response	—	rejected	EID2140 In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5% vs.… (full text at CIViC) PMID 21882184 · Kim et al., 2012 · Open in CIViC	civic
BRAF V600E	RDEA 119	Predictive	B	Supports Sensitivity Response	—	rejected	EID2141 In a study of 102 papillary thyroid cancer patients with a 15 year median follow-up time, those with BRAF V600E mutations had reduced overall survival compared to those with wildtype BRAF (P=0.015, lo… (full text at CIViC) PMID 18682506 · Elisei et al., 2008 · Open in CIViC	civic
BRAF V600E	RDEA 119	Predictive	D	Supports Sensitivity Response	—	submitted	EID2139 Thyroid cancer cell lines with BRAF V600E mutations were more sensitive to the MEK inhibitor RDEA119 than those with wildtype BRAF (IC50: 0.034-0.217 uM vs. 1.413-34.120 uM). PMID 21351275 · Liu et al., 2010 · Open in CIViC	civic
BRAF V600E	Sorafenib	Predictive	B	Supports Sensitivity Response	—	rejected	EID2504 In a study of 102 papillary thyroid cancer patients with a 15 year median follow-up time, those with BRAF V600E mutations had reduced overall survival compared to those with wildtype BRAF (P=0.015, lo… (full text at CIViC) PMID 18682506 · Elisei et al., 2008 · Open in CIViC	civic
BRAF V600E	Sorafenib	Predictive	D	Supports Sensitivity Response	—	submitted	EID2142 Following treatment with sorafenib, thyroid cancer cell lines with BRAF V600E mutations had severely reduced proliferation rates, but cells with wildtype BRAF were insensitive (P<0.0001). PMID 16533790 · Salvatore et al., 2006 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	D	Supports Sensitivity Response	—	submitted	EID3760 Thyroid cancer cell lines with BRAF V600E mutations were more sensitive to vemurafenib than those with wildtype BRAF (IC50: 0.115� 1.156 uM vs. 56.674�1349.788 uM). PMID 18458053 · Sala et al., 2008 · Open in CIViC	civic

Malignant Thyroid Gland Neoplasm11

BRAF V600E

(diagnostic)

Diagnostic

Supports Positive

accepted

EID79

BRAF V600E is shown to be associated with the tall-cell variant of papillary thyroid cancer.

PMID 21594703 · Howell et al., 2011 · Open in CIViC

civic

BRAF V600E

MEK Inhibitor CI-1040

Predictive

Supports Sensitivity Response

—

rejected

EID2138

In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5% vs.… (full text at CIViC)

PMID 21882184 · Kim et al., 2012 · Open in CIViC

civic

BRAF V600E

MEK Inhibitor CI-1040

Predictive

Supports Sensitivity Response

—

submitted

EID2136

Thyroid cancer cell lines with BRAF V600E mutations were more sensitive to the MAPK inhibitor CI-1040 than those with wildtype BRAF (IC50: 0.031-1.251 uM vs. 44.376-278.286 uM). In a mouse xenograft m… (full text at CIViC)

PMID 17911174 · Liu et al., 2007 · Open in CIViC

civic

BRAF V600E

PLX4720 + PonatinibCombination

Predictive

Supports Sensitivity Response

submitted

EID8033

Ghosh et al. provide compelling evidence that thyroid cancers with a BRAFV600E mutation are sensitive to combined PLX4720 and Ponatinib treatment. They predicted a synergistic effect using HTS of acti… (full text at CIViC)

PMID 31937621 · Ghosh et al., 2020 · Open in CIViC

civic

BRAF V600E

PLX4720 + PonatinibCombination

Predictive

Supports Sensitivity Response

submitted

EID8040

Both in vitro and in vivo models in Kebebew et al. provide evidence that a combinatorial treatment of PLX4720 (a BRAF inhibitor) and ponatinib (a multi targeting tyrosine kinase inhibitor) shows poten… (full text at CIViC)

PMID 31937621 · Ghosh et al., 2020 · Open in CIViC

civic

BRAF V600E

RDEA 119

Predictive

Supports Sensitivity Response

—

rejected

EID2140

PMID 21882184 · Kim et al., 2012 · Open in CIViC

civic

BRAF V600E

RDEA 119

Predictive

Supports Sensitivity Response

—

rejected

EID2141

In a study of 102 papillary thyroid cancer patients with a 15 year median follow-up time, those with BRAF V600E mutations had reduced overall survival compared to those with wildtype BRAF (P=0.015, lo… (full text at CIViC)

PMID 18682506 · Elisei et al., 2008 · Open in CIViC

civic

BRAF V600E

RDEA 119

Predictive

Supports Sensitivity Response

—

submitted

EID2139

Thyroid cancer cell lines with BRAF V600E mutations were more sensitive to the MEK inhibitor RDEA119 than those with wildtype BRAF (IC50: 0.034-0.217 uM vs. 1.413-34.120 uM).

PMID 21351275 · Liu et al., 2010 · Open in CIViC

civic

BRAF V600E

Sorafenib

Predictive

Supports Sensitivity Response

—

rejected

EID2504

PMID 18682506 · Elisei et al., 2008 · Open in CIViC

civic

BRAF V600E

Sorafenib

Predictive

Supports Sensitivity Response

—

submitted

EID2142

Following treatment with sorafenib, thyroid cancer cell lines with BRAF V600E mutations had severely reduced proliferation rates, but cells with wildtype BRAF were insensitive (P<0.0001).

PMID 16533790 · Salvatore et al., 2006 · Open in CIViC

civic

BRAF V600E

Vemurafenib

Predictive

Supports Sensitivity Response

—

submitted

EID3760

Thyroid cancer cell lines with BRAF V600E mutations were more sensitive to vemurafenib than those with wildtype BRAF (IC50: 0.115� 1.156 uM vs. 56.674�1349.788 uM).

PMID 18458053 · Sala et al., 2008 · Open in CIViC

civic

Melanoma10
AKT1 E17K AND BRAF V600E	Uprosertib	Predictive	D	Supports Sensitivity Response	2	accepted	EID707 A melanoma cell line (M262) with AKT E17K mutation was found to be sensitive to AKT inhibition with GSK2141795B in this study. PMID 24735930 · Lassen et al., 2014 · Open in CIViC	civic
AKT1 E17K AND BRAF V600E	Dabrafenib + UprosertibCombination	Predictive	D	Supports Sensitivity Response	2	submitted	EID13115 A BRAF V600E-positive melanoma cell line (M262) with AKT E17K mutation was found to have a similar level of sensitivity to combination dabrafenib plus AKT inhibitor GSK2141795B (IC50 < 1nM) as to dabr… (full text at CIViC) PMID 24735930 · Lassen et al., 2014 · Open in CIViC	civic
BRAF Amplification AND ( BRAF V600E OR BRAF V600K )	Dabrafenib + VemurafenibSubstitutes	Predictive	B	Supports Resistance	2	accepted	EID6262 In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired r… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic
BRAF V600E	(prognostic)	Prognostic	B	Does Not Support Poor Outcome	2	accepted	EID82 BRAF status does not predict outcome in patients treated with dacarbazine or temozolomide. PMID 24586605 · Meckbach et al., 2014 · Open in CIViC	civic
BRAF V600E	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID104 BRAF V600E is correlated with shorter disease-free and overall Survival in a Spanish cohort of melanoma patients. PMID 24388723 · Nagore et al., 2014 · Open in CIViC	civic
BRAF V600E	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID13053 In this study, BRAF V600E, reported as V599E, was identified as a recurrent somatic variant in melanoma. When transiently expressed in COS cells, BRAF V600E demonstrated approximately 10.7-fold greate… (full text at CIViC) PMID 12068308 · Davies et al., 2002 · Open in CIViC	civic
BRAF V600E	(oncogenic)	Oncogenic	D	Supports Oncogenicity	2	submitted	EID13054 In this study, conditional melanocyte-specific expression of BRAF V600E in mice induced benign melanocytic hyperplasia that did not progress to melanoma during 15–20 months of follow-up. In contrast, … (full text at CIViC) PMID 19282848 · Dankort et al., 2009 · Open in CIViC	civic
BRAF V600E	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID13056 In this study, sustained expression of BRAF V600E in primary human melanocytes initially increased proliferation but subsequently induced stable cell-cycle arrest accompanied by senescence-associated … (full text at CIViC) PMID 16079850 · Michaloglou et al., 2005 · Open in CIViC	civic
BRAF V600E	Atezolizumab + Cobimetinib + VemurafenibCombination	Predictive	A	Supports Sensitivity Response	4	submitted	EID13045 In an exploratory biomarker analysis of the randomized, double-blind, placebo-controlled phase III IMspire150 trial (NCT02908672), 379 patients with centrally confirmed BRAF V600E-mutated, previously … (full text at CIViC) PMID 35131452 · Robert et al., 2022 · Open in CIViC	civic
BRAF V600E	Dabrafenib	Predictive	A	Supports Sensitivity Response	4	submitted	EID11244 In an open-label, phase 3 randomized trial, 250 patients with either previously untreated, stage IV or unresectable stage III BRAF V600E mutation-positive melanoma were randomly assigned (3:1) to rece… (full text at CIViC) PMID 22735384 · Hauschild et al., 2012 · Open in CIViC	civic

Melanoma10

AKT1 E17K AND BRAF V600E

Uprosertib

Predictive

Supports Sensitivity Response

accepted

EID707

A melanoma cell line (M262) with AKT E17K mutation was found to be sensitive to AKT inhibition with GSK2141795B in this study.

PMID 24735930 · Lassen et al., 2014 · Open in CIViC

civic

AKT1 E17K AND BRAF V600E

Dabrafenib + UprosertibCombination

Predictive

Supports Sensitivity Response

submitted

EID13115

A BRAF V600E-positive melanoma cell line (M262) with AKT E17K mutation was found to have a similar level of sensitivity to combination dabrafenib plus AKT inhibitor GSK2141795B (IC50 < 1nM) as to dabr… (full text at CIViC)

PMID 24735930 · Lassen et al., 2014 · Open in CIViC

civic

BRAF Amplification AND ( BRAF V600E OR BRAF V600K )

Dabrafenib + VemurafenibSubstitutes

Predictive

Supports Resistance

accepted

EID6262

In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired r… (full text at CIViC)

PMID 24265155 · Shi et al., 2014 · Open in CIViC

civic

BRAF V600E

(prognostic)

Prognostic

Does Not Support Poor Outcome

accepted

EID82

BRAF status does not predict outcome in patients treated with dacarbazine or temozolomide.

PMID 24586605 · Meckbach et al., 2014 · Open in CIViC

civic

BRAF V600E

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID104

BRAF V600E is correlated with shorter disease-free and overall Survival in a Spanish cohort of melanoma patients.

PMID 24388723 · Nagore et al., 2014 · Open in CIViC

civic

BRAF V600E

(oncogenic)

Oncogenic

Supports Oncogenicity

submitted

EID13053

In this study, BRAF V600E, reported as V599E, was identified as a recurrent somatic variant in melanoma. When transiently expressed in COS cells, BRAF V600E demonstrated approximately 10.7-fold greate… (full text at CIViC)

PMID 12068308 · Davies et al., 2002 · Open in CIViC

civic

BRAF V600E

(oncogenic)

Oncogenic

Supports Oncogenicity

submitted

EID13054

In this study, conditional melanocyte-specific expression of BRAF V600E in mice induced benign melanocytic hyperplasia that did not progress to melanoma during 15–20 months of follow-up. In contrast, … (full text at CIViC)

PMID 19282848 · Dankort et al., 2009 · Open in CIViC

civic

BRAF V600E

(oncogenic)

Oncogenic

Supports Oncogenicity

submitted

EID13056

In this study, sustained expression of BRAF V600E in primary human melanocytes initially increased proliferation but subsequently induced stable cell-cycle arrest accompanied by senescence-associated … (full text at CIViC)

PMID 16079850 · Michaloglou et al., 2005 · Open in CIViC

civic

BRAF V600E

Atezolizumab + Cobimetinib + VemurafenibCombination

Predictive

Supports Sensitivity Response

submitted

EID13045

In an exploratory biomarker analysis of the randomized, double-blind, placebo-controlled phase III IMspire150 trial (NCT02908672), 379 patients with centrally confirmed BRAF V600E-mutated, previously … (full text at CIViC)

PMID 35131452 · Robert et al., 2022 · Open in CIViC

civic

BRAF V600E

Dabrafenib

Predictive

Supports Sensitivity Response

submitted

EID11244

In an open-label, phase 3 randomized trial, 250 patients with either previously untreated, stage IV or unresectable stage III BRAF V600E mutation-positive melanoma were randomly assigned (3:1) to rece… (full text at CIViC)

PMID 22735384 · Hauschild et al., 2012 · Open in CIViC

civic

Evidence by cancer (259 items)

Clinical significance (0)